A STUDY TO DECREASE QUANTITY OF ROPIVACAINE WITH DEXMEDETOMIDINE IN ULTRASOUND GUIDED SUPRACLAVICULAR BRACHIAL PLEXUS BLOCK IN FOREARM AND HAND SURGERIES

A STUDY TO FIND OUT MINIMUM EFFECTIVE VOLUME OF 0.5% ROPIVACAINE WITH DEXMEDETOMIDINE AS AN ADJUVANT IN ULTRASOUND GUIDED SUPRACLAVICULAR BRACHIAL PLEXUS NERVE BLOCK FOR ELECTIVE FOREARM AND HAND SURGERIES

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2022/07/044034

Enrollment

Registered

2022-07-15

Start date

Unknown

Completion date

Unknown

Last updated

2022-08-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: S529- Unspecified fracture of forearm

Interventions

Intervention1: DEXMEDETOMIDINE: 2microgram per kg added with 0.5% Ropivacaine for supraclavicular brachial plexus nerve block Control Intervention1: NIL: NIL

Eligibility

Inclusion criteria

Inclusion criteria: ASA GRADE 1 AND 2 SURGERY TYPE- ELECTIVE FOREARM AND HAND SURGERIES

Exclusion criteria

Exclusion criteria: PATIENTS WHO REFUSE TO BE PART OF THE SYUDY SIGNIFICANT COAGULOPATHIES HISTORY OF BRACHIAL PLEXUS INJURY ALLERGY TO STUDY DRUG PSYCHIATRIC HISTORY INFECTION AT THE SITE OF INJECTION PREGNANT PATIENTS DIAPHRAGMATIC PARALYSIS

Design outcomes

Primary

Measure	Time frame
TO DETERMINE MINIMUM VOLUME OF 0.5% ROPIVACAINE WITH DEXMEDETOMIDINE IN USG GUIDED SUPRACLAVICULAR BRACHIAL PLEXUS BLOCK REQUIRED TO GET SURGICAL ANAESTHESIA IN FOREARM AND HAND SURGERYTimepoint: WITHIN 30 MINUTES OF ADMINISTRATION OF DRUG	—

Secondary

Measure	Time frame
ASSESSMENT OF BLOCK IN TERMS OF ONSET AND DURATION OF SENSORY AND MOTOR BLOCK MONITORING OF HAEMODYNAMIC PARAMETERSTimepoint: 6 HOURS ;TIME OF FIRST RESCUE ANALGESIC ADMINISTRATION ADVERSE EFFECTSTimepoint: APPROX 24 HOURS	—

Countries

India

Contacts

Public ContactDR CHANDA KHATRI

DR. S.N.MEDICAL COLLEGE, JODHPUR

gehlot.payal111@gmail.com8955925849

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026